This follows a licensing agreement between the two companies authorizing Ranbaxy to promote and market the drug in India.
Olvance (olmesartan medoxomil) is an antihypertensive agent that can be administered once daily. The clinical trials of olmesartan have shown it to be significantly more effective at reducing blood pressure than several other agents, said Daiichi Sankyo.
Takashi Shoda, president and CEO of Daiichi Sankyo, said: “We are delighted with the introduction of Olvance in the Indian market by Ranbaxy, signifying our serious commitment to India. Olmesartan medoxomil is a superior antihypertensive medicine that will offer an excellent therapy option to the doctors and patients in India. This marks our intent to scale up our innovative product introductions, in India, through Ranbaxy.”